The Impact of Red Cell Substitutes on the Blood Service in Japan

The total number of blood donors in 1994 was 6.6 millions, and 200 ml whole blood donation occupied 41.8 % of all donations, whereas 400 ml and apheresis donations occupied 35.6 %, 22.5 % of all donations respectively. From the donated blood, about 8.35 million bags of blood components were prepared...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Artificial cells, blood substitutes, and immobilization biotechnology blood substitutes, and immobilization biotechnology, 1997, Vol.25 (1-2), p.53-60
1. Verfasser: Sekiguchi, Sadayoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 60
container_issue 1-2
container_start_page 53
container_title Artificial cells, blood substitutes, and immobilization biotechnology
container_volume 25
creator Sekiguchi, Sadayoshi
description The total number of blood donors in 1994 was 6.6 millions, and 200 ml whole blood donation occupied 41.8 % of all donations, whereas 400 ml and apheresis donations occupied 35.6 %, 22.5 % of all donations respectively. From the donated blood, about 8.35 million bags of blood components were prepared and were used for blood transfusion. Besides used as blood components, 720,000 L source plasma was used to produce plasma derivatives, and therefore Japan has achieved self-sufficiency in Factor VIII by donated blood. Blood transfusion has become quite safer but there are still risks of acquiring transfusion-associated GVHD(TA-GVHD) or infecting with HIV from blood in window period. To avoid adverse reactions of blood transfusion, the strategies for reducing homologous blood transfusion has been promoting. The use of red cell substitutes will be an option of using non-human derived substitutes toward "zero" adverse reaction of transfusion, and when red cell substitutes are accepted in Japan, they will be applied as the substitution to allogeneic blood transfusion below 1200 ml hemorrhage. They will also be applied as an alternation to and/or combination with allogeneic and autologous blood transfusion and the use of erythropoietin.
doi_str_mv 10.3109/10731199709118897
format Article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_78908894</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78908894</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-45e4009eb6cd61bacdf201bd1d4951d53e7ce8e536df986d0f8b8372f51bd6d53</originalsourceid><addsrcrecordid>eNqFkE9r3DAQxUVJyL_2A_QQ0Ck3pxrLsiXaQ9IlbRMChSY9G1kasQ62tZHkhnz7aNmlEEKS0wy833vMPEI-AzvlwNQXYA0HUKphCkBK1XwgByB4WVQgq528Z71YA_vkMMY7xhivoNwje4pJXpf1ATm7XSK9HFfaJOod_YOWLnAY6M3cxdSnOWGkfqIpU98H7y29wfCvN0j7iV7plZ4-kl2nh4iftvOI_P1xcbv4VVz__nm5OL8ujKggFZXAijGFXW1sDZ021pUMOgu2UgKs4NgYlCh4bZ2StWVOdpI3pRMZqrN-RE42uavg72eMqR37aPKpekI_x7aR-SepqndBEEo2TPAMwgY0wccY0LWr0I86PLbA2nW97Yt6s-d4Gz53I9r_jm2fWf-20fvJ-TDqBx8G2yb9OPjggp5MH9fRr8d_fWZfoh7S0uiA7Z2fw5QLfuO4JzWrmN8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15987053</pqid></control><display><type>article</type><title>The Impact of Red Cell Substitutes on the Blood Service in Japan</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Taylor &amp; Francis E-Journals</source><creator>Sekiguchi, Sadayoshi</creator><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><description>The total number of blood donors in 1994 was 6.6 millions, and 200 ml whole blood donation occupied 41.8 % of all donations, whereas 400 ml and apheresis donations occupied 35.6 %, 22.5 % of all donations respectively. From the donated blood, about 8.35 million bags of blood components were prepared and were used for blood transfusion. Besides used as blood components, 720,000 L source plasma was used to produce plasma derivatives, and therefore Japan has achieved self-sufficiency in Factor VIII by donated blood. Blood transfusion has become quite safer but there are still risks of acquiring transfusion-associated GVHD(TA-GVHD) or infecting with HIV from blood in window period. To avoid adverse reactions of blood transfusion, the strategies for reducing homologous blood transfusion has been promoting. The use of red cell substitutes will be an option of using non-human derived substitutes toward "zero" adverse reaction of transfusion, and when red cell substitutes are accepted in Japan, they will be applied as the substitution to allogeneic blood transfusion below 1200 ml hemorrhage. They will also be applied as an alternation to and/or combination with allogeneic and autologous blood transfusion and the use of erythropoietin.</description><identifier>ISSN: 1073-1199</identifier><identifier>EISSN: 1532-4184</identifier><identifier>DOI: 10.3109/10731199709118897</identifier><identifier>PMID: 9083626</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>AIDS/HIV ; Blood Banks - statistics &amp; numerical data ; Blood Banks - trends ; Blood Component Transfusion - adverse effects ; Blood Component Transfusion - statistics &amp; numerical data ; Blood Component Transfusion - utilization ; Blood Substitutes ; Graft vs Host Disease - prevention &amp; control ; HIV Infections - prevention &amp; control ; HIV Infections - transmission ; HTLV-I Infections - prevention &amp; control ; HTLV-I Infections - transmission ; Humans ; Japan ; Risk Factors</subject><ispartof>Artificial cells, blood substitutes, and immobilization biotechnology, 1997, Vol.25 (1-2), p.53-60</ispartof><rights>1997 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1997</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-45e4009eb6cd61bacdf201bd1d4951d53e7ce8e536df986d0f8b8372f51bd6d53</citedby><cites>FETCH-LOGICAL-c541t-45e4009eb6cd61bacdf201bd1d4951d53e7ce8e536df986d0f8b8372f51bd6d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10731199709118897$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10731199709118897$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9083626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><title>The Impact of Red Cell Substitutes on the Blood Service in Japan</title><title>Artificial cells, blood substitutes, and immobilization biotechnology</title><addtitle>Artif Cells Blood Substit Immobil Biotechnol</addtitle><description>The total number of blood donors in 1994 was 6.6 millions, and 200 ml whole blood donation occupied 41.8 % of all donations, whereas 400 ml and apheresis donations occupied 35.6 %, 22.5 % of all donations respectively. From the donated blood, about 8.35 million bags of blood components were prepared and were used for blood transfusion. Besides used as blood components, 720,000 L source plasma was used to produce plasma derivatives, and therefore Japan has achieved self-sufficiency in Factor VIII by donated blood. Blood transfusion has become quite safer but there are still risks of acquiring transfusion-associated GVHD(TA-GVHD) or infecting with HIV from blood in window period. To avoid adverse reactions of blood transfusion, the strategies for reducing homologous blood transfusion has been promoting. The use of red cell substitutes will be an option of using non-human derived substitutes toward "zero" adverse reaction of transfusion, and when red cell substitutes are accepted in Japan, they will be applied as the substitution to allogeneic blood transfusion below 1200 ml hemorrhage. They will also be applied as an alternation to and/or combination with allogeneic and autologous blood transfusion and the use of erythropoietin.</description><subject>AIDS/HIV</subject><subject>Blood Banks - statistics &amp; numerical data</subject><subject>Blood Banks - trends</subject><subject>Blood Component Transfusion - adverse effects</subject><subject>Blood Component Transfusion - statistics &amp; numerical data</subject><subject>Blood Component Transfusion - utilization</subject><subject>Blood Substitutes</subject><subject>Graft vs Host Disease - prevention &amp; control</subject><subject>HIV Infections - prevention &amp; control</subject><subject>HIV Infections - transmission</subject><subject>HTLV-I Infections - prevention &amp; control</subject><subject>HTLV-I Infections - transmission</subject><subject>Humans</subject><subject>Japan</subject><subject>Risk Factors</subject><issn>1073-1199</issn><issn>1532-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9r3DAQxUVJyL_2A_QQ0Ck3pxrLsiXaQ9IlbRMChSY9G1kasQ62tZHkhnz7aNmlEEKS0wy833vMPEI-AzvlwNQXYA0HUKphCkBK1XwgByB4WVQgq528Z71YA_vkMMY7xhivoNwje4pJXpf1ATm7XSK9HFfaJOod_YOWLnAY6M3cxdSnOWGkfqIpU98H7y29wfCvN0j7iV7plZ4-kl2nh4iftvOI_P1xcbv4VVz__nm5OL8ujKggFZXAijGFXW1sDZ021pUMOgu2UgKs4NgYlCh4bZ2StWVOdpI3pRMZqrN-RE42uavg72eMqR37aPKpekI_x7aR-SepqndBEEo2TPAMwgY0wccY0LWr0I86PLbA2nW97Yt6s-d4Gz53I9r_jm2fWf-20fvJ-TDqBx8G2yb9OPjggp5MH9fRr8d_fWZfoh7S0uiA7Z2fw5QLfuO4JzWrmN8</recordid><startdate>1997</startdate><enddate>1997</enddate><creator>Sekiguchi, Sadayoshi</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>1997</creationdate><title>The Impact of Red Cell Substitutes on the Blood Service in Japan</title><author>Sekiguchi, Sadayoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-45e4009eb6cd61bacdf201bd1d4951d53e7ce8e536df986d0f8b8372f51bd6d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>AIDS/HIV</topic><topic>Blood Banks - statistics &amp; numerical data</topic><topic>Blood Banks - trends</topic><topic>Blood Component Transfusion - adverse effects</topic><topic>Blood Component Transfusion - statistics &amp; numerical data</topic><topic>Blood Component Transfusion - utilization</topic><topic>Blood Substitutes</topic><topic>Graft vs Host Disease - prevention &amp; control</topic><topic>HIV Infections - prevention &amp; control</topic><topic>HIV Infections - transmission</topic><topic>HTLV-I Infections - prevention &amp; control</topic><topic>HTLV-I Infections - transmission</topic><topic>Humans</topic><topic>Japan</topic><topic>Risk Factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Sekiguchi, Sadayoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial cells, blood substitutes, and immobilization biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sekiguchi, Sadayoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Red Cell Substitutes on the Blood Service in Japan</atitle><jtitle>Artificial cells, blood substitutes, and immobilization biotechnology</jtitle><addtitle>Artif Cells Blood Substit Immobil Biotechnol</addtitle><date>1997</date><risdate>1997</risdate><volume>25</volume><issue>1-2</issue><spage>53</spage><epage>60</epage><pages>53-60</pages><issn>1073-1199</issn><eissn>1532-4184</eissn><abstract>The total number of blood donors in 1994 was 6.6 millions, and 200 ml whole blood donation occupied 41.8 % of all donations, whereas 400 ml and apheresis donations occupied 35.6 %, 22.5 % of all donations respectively. From the donated blood, about 8.35 million bags of blood components were prepared and were used for blood transfusion. Besides used as blood components, 720,000 L source plasma was used to produce plasma derivatives, and therefore Japan has achieved self-sufficiency in Factor VIII by donated blood. Blood transfusion has become quite safer but there are still risks of acquiring transfusion-associated GVHD(TA-GVHD) or infecting with HIV from blood in window period. To avoid adverse reactions of blood transfusion, the strategies for reducing homologous blood transfusion has been promoting. The use of red cell substitutes will be an option of using non-human derived substitutes toward "zero" adverse reaction of transfusion, and when red cell substitutes are accepted in Japan, they will be applied as the substitution to allogeneic blood transfusion below 1200 ml hemorrhage. They will also be applied as an alternation to and/or combination with allogeneic and autologous blood transfusion and the use of erythropoietin.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>9083626</pmid><doi>10.3109/10731199709118897</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1073-1199
ispartof Artificial cells, blood substitutes, and immobilization biotechnology, 1997, Vol.25 (1-2), p.53-60
issn 1073-1199
1532-4184
language eng
recordid cdi_proquest_miscellaneous_78908894
source MEDLINE; Alma/SFX Local Collection; Taylor & Francis E-Journals
subjects AIDS/HIV
Blood Banks - statistics & numerical data
Blood Banks - trends
Blood Component Transfusion - adverse effects
Blood Component Transfusion - statistics & numerical data
Blood Component Transfusion - utilization
Blood Substitutes
Graft vs Host Disease - prevention & control
HIV Infections - prevention & control
HIV Infections - transmission
HTLV-I Infections - prevention & control
HTLV-I Infections - transmission
Humans
Japan
Risk Factors
title The Impact of Red Cell Substitutes on the Blood Service in Japan
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A26%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Red%20Cell%20Substitutes%20on%20the%20Blood%20Service%20in%20Japan&rft.jtitle=Artificial%20cells,%20blood%20substitutes,%20and%20immobilization%20biotechnology&rft.au=Sekiguchi,%20Sadayoshi&rft.date=1997&rft.volume=25&rft.issue=1-2&rft.spage=53&rft.epage=60&rft.pages=53-60&rft.issn=1073-1199&rft.eissn=1532-4184&rft_id=info:doi/10.3109/10731199709118897&rft_dat=%3Cproquest_infor%3E78908894%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15987053&rft_id=info:pmid/9083626&rfr_iscdi=true